OpenAI Rejects Apple Trade Secret Theft Claims 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Shein Shares Slide 9% in Hong Kong IPO Debut 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
Add as a preferred source on Google
CANTON, Mass., March 16, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at the following investor conferences in March:
- The Oppenheimer & Company 28th Annual Healthcare Conference on Wednesday, March 21st at 9:10 a.m. ET in New York City
- The Needham 17th Annual Healthcare Conference on Wednesday, March 28th at 10:30 a.m. ET in New York City
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
